Returning for its 7th year, IMPACCT: RWE provides top innovators and leaders in the RWE space with a comprehensive industry forum dedicated to supporting and advancing the generation and utilization of real world evidence across drug life cycle, from clinical development to commercialization.
Join your peers and leading experts in this space for a collaborative open discussion aiming to tackle key challenges to accelerate the meaningful implementation of RWE-approaches to enhance clinical RandD outcomes, drive patient-centricity, and maximize the success of launch and commercialization activities.
This collaborative discussion platform will bring together stakeholders from functions across clinical development, HEOR, regulatory and medical affairs, epidemiology and RWE, to overcome key challenges to define and implement a meaningful evidence generation plan that can effectively enhance clinical RandD, support regulatory submission and decision-making, and ultimately drive commercial success.
2-Day Conference: USD 2399.0,
2-Day Conference Academic Rate: USD 1400.0
Speakers: CJ Hameed, Senior Director - Global RWE Center of Excellence, Pfizer, Danny Wiederkehr, Senior Director, Global HEOR Team Lead, Pfizer, David Anstatt, Executive Director, Observational Research and Data Sciences, Bristol-Myers Squibb, Frank Zhang, VP, Head of Market Access, uniQure, Javier Jimenez, VP and Global Head of RWE and Clinical Outcomes, Sanofi, John Graham, SVP, Value, Evidence and Outcomes, GlaxoSmithKline, Judy Kando, VP, Head of Medical Affairs, Tris Pharma, Keith Friend, Global Medical Director, Cardiovascular, Bristol-Myers Squibb, Leona Bessonova, Director – HEOR, Alkermes, Marla Curran, Executive Director, Head of Biometrics and Medical Writing, Paratek Pharmaceuticals, Melvin Olson, Global Head, RWD Strategy and Innovation, Novartis, Michael Lees, Head of Value, Evidence and Portfolio Strategy, Takeda, Ravi Iyer, Director, Global HEOR, Teva Pharmaceuticals, Sandy Leonard, Former VP, Medical Evidence and Observational Research, AstraZeneca, Sebastian Schneeweiss, Professor, Harvard Medical School, Tony Hebden, VP HEOR, AbbVie